Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) announced its earnings results on Thursday. Viridian Therapeutics had a negative net margin of 490.31% and a negative return on equity of 80.19%. Viridian Therapeutics Price PerformanceNASDAQ:VRDN traded up $1.08 on Friday, reaching $23.59. According to MarketBeat.com, Viridian Therapeutics has an average rating of “Moderate Buy” and an average price target of $38.93. Featured StoriesReceive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.